Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_assertion type Assertion NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_head.
- NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_assertion description "[The mean log(10) HCV RNA differences for the best-performing CAP/CTM v2/MMx2 formulation in comparison to CAM were -0.05, 0.05, -0.12, -0.10, -0.44, and -0.29 for patients with GT1, GT2, GT3, GT4, GT5, and GT6 infections, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_provenance.
- NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_assertion evidence source_evidence_literature NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_provenance.
- NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_assertion SIO_000772 21752967 NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_provenance.
- NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_assertion wasDerivedFrom befree-20140225 NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_provenance.
- NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_assertion wasGeneratedBy ECO_0000203 NP298970.RAlHpUL6bF7_Kujv-HnZWe42PQ7vIOnLyHuG4LuMOq0v8130_provenance.